Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 2/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31525522 | 0.86 | TRPV4 (0.47) | SMN1; SMN2ALDH1A1KMT2AALPLTRPV4 | |
| SCHEMBL1036692 | 0.86 | ALPL (0.52) | SMN1; SMN2ALDH1A1KMT2AALPLTRPV4 | |
| SCHEMBL2747879 | 0.86 | TRPV4 (0.64) | SMN1; SMN2ALDH1A1KMT2AALPLTRPV4 | |
| SCHEMBL30440381 | 0.86 | TRPV4 (0.64) | SMN1; SMN2ALDH1A1KMT2AALPLTRPV4 | |
| SCHEMBL10710253 | 0.84 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1KMT2AALPLCA1 | |
| SCHEMBL8646151 | 0.83 | TRPV4 (0.45) | SMN1; SMN2ALDH1A1KMT2AALPLTRPV4 | |
| SCHEMBL10642296 | 0.83 | TRPV4 (0.45) | SMN1; SMN2ALDH1A1KMT2AALPLTRPV4 | |
| SCHEMBL4193369 | 0.82 | TRPV4 (0.44) | SMN1; SMN2ALDH1A1KMT2AALPLTRPV4 | |
| SCHEMBL2446085 | 0.82 | CA2 (0.57) | SMN1; SMN2ALDH1A1KMT2AALPLCA1 | |
| SCHEMBL11148251 | 0.82 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1KMT2AALPLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741375-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023114710-A1 | FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-0313311-A2 | Herbicidal sulfonamides | ICI AUSTRALIA OPERATIONS PROPRIETARY LIMITED (AU) | 1989-04-26 | — | — | EP | disclosed |
| US-4766241-A | LOWER ACUTE TOXICITY | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-23 | — | — | US | disclosed |
| EP-0135860-B1 | DERIVATIVES OF 6-SULFOXYPHENOL, THEIR PREPARATION AND THEIR USE AS CYTOPROTECTORS; USE OF DERIVATIVES OF SALICYLALDEHYDE AS CYTOPROTECTORS | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-03-02 | — | — | EP | disclosed |
| US-4661636-A | 6-sulfoxyphenol derivatives, their preparation and their use as cytoprotective agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-28 | — | — | US | disclosed |
| US-4607030-A | ANTIEDEMICS, HYPOTENSIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-08-19 | — | — | US | disclosed |
| EP-0144969-A2 | Process for the preparation of 2-alkylsulfonyl-4-alkyl-phenols | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0088346-B1 | 2-AMINOMETHYL-PHENOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-06-05 | — | — | EP | disclosed |
| EP-0135860-A2 | Derivatives of 6-sulfoxyphenol, their preparation and their use as cytoprotectors; use of derivatives of salicylaldehyde as cytoprotectors | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-04-03 | — | — | EP | disclosed |
| EP-0088345-A2 | 2-Aminomethyl-6-sulfamoylphenol derivatives, process for their preparation, their use and pharmaceutical preparations based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
| EP-0088346-A2 | 2-Aminomethyl-phenol derivatives, process for their preparation, their use and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | SMN1; SMN2 3192/4885ALDH1A1 3906/4885KMT2A 161/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | SMN1; SMN2 538/4885ALDH1A1 4542/4885KMT2A 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.